Payload Information

General Information of This Payload

Payload ID	PAY0PKYCM
Name	SC209
Synonyms	SC209 Click to Show/Hide
Target(s)	Microtubule (MT)	Target Info

The activity data of This Payload

Standard Type	Value	Units	Cell line	Disease Model	Cell line ID	Reference
Half-maximal effective concentration (EC50)	0.24	nmol/L	NCI-H1703 cells	Lung squamous cell carcinoma	CVCL_1490	[1]
Half-maximal effective concentration (EC50)	0.74	nmol/L	MDA-MB-468 cells	Breast adenocarcinoma	CVCL_0419	[1]
Half-maximal effective concentration (EC50)	0.84	nmol/L	NCI-H2110 cells	Lung non-small cell carcinoma	CVCL_1530	[1]
Half-maximal effective concentration (EC50)	1.4	nmol/L	A431 cells	Skin squamous cell carcinoma	CVCL_0037	[1]
Half-maximal effective concentration (EC50)	1.42	nmol/L	SK-BR-3 cells	Breast adenocarcinoma	CVCL_0033	[1]
Half-maximal effective concentration (EC50)	1.42	nmol/L	SU-DHL-6 cells	Diffuse large B-cell lymphoma	CVCL_2206	[1]
Half-maximal effective concentration (EC50)	1.6	nmol/L	Ishikawa cells	Endometrial adenocarcinoma	CVCL_2529	[1]
Half-maximal effective concentration (EC50)	1.7	nmol/L	MDA-MB-231 cells	Breast adenocarcinoma	CVCL_0062	[1]
Half-maximal effective concentration (EC50)	1.8	nmol/L	MDA-MB-453 cells	Breast adenocarcinoma	CVCL_0418	[1]
Half-maximal effective concentration (EC50)	2.1	nmol/L	NCI-N87 cells	Gastric tubular adenocarcinoma	CVCL_1603	[1]
Half-maximal effective concentration (EC50)	2.2	nmol/L	KB cells	Human papillomavirus-related endocervical adenocarcinoma	CVCL_0372	[1]
Half-maximal effective concentration (EC50)	2.2	nmol/L	IGROV-1 cells	Ovarian endometrioid adenocarcinoma	CVCL_1304	[1]
Half-maximal effective concentration (EC50)	2.29	nmol/L	MDA-MB-435 cells	Amelanotic melanoma	CVCL_0417	[1]
Half-maximal effective concentration (EC50)	2.42	nmol/L	OPM-2 cells	Plasma cell myeloma	CVCL_1625	[1]
Half-maximal effective concentration (EC50)	2.8	nmol/L	OVKATE cells	High grade ovarian serous adenocarcinoma	CVCL_3110	[1]
Half-maximal effective concentration (EC50)	3.18	nmol/L	HT29 cells	Colon cancer	CVCL_A8EZ	[1]
Half-maximal effective concentration (EC50)	3.59	nmol/L	SK-CO-1 cells	Colon adenocarcinoma	CVCL_0626	[1]
Half-maximal effective concentration (EC50)	7.9	nmol/L	A-549 cells	Lung adenocarcinoma	CVCL_0023	[1]
Half-maximal effective concentration (EC50)	9.18	nmol/L	HCT 116 cells	Colon cancer	CVCL_0291	[1]
Half-maximal effective concentration (EC50)	9.2	nmol/L	NCI-H1651 cells	Lung adenocarcinoma	CVCL_1484	[1]

Each Antibody-drug Conjugate Related to This Payload

Full Information of The Activity Data of The ADC(s) Related to This Payload

Luveltamab tazevibulin [Phase 2]

ADC Info

Discovered Using Patient-derived Xenograft Model

Click To Hide/Show 6 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[2]
Efficacy Data	Tumor Growth Inhibition value (TGI)	15.00%	Negative FOLR1 expression (FOLR1-)
In Vivo Model	STRO-002 monotherapy PDX model (PDX:PDX model 5)
Experiment 2 Reporting the Activity Date of This ADC				[2]
Efficacy Data	Tumor Growth Inhibition value (TGI)	53.00%	Low FOLR1 expression (FOLR1+)
In Vivo Model	PDX model
Experiment 3 Reporting the Activity Date of This ADC				[2]
Efficacy Data	Tumor Growth Inhibition value (TGI)	70.00%	Moderate FOLR1 expression (FOLR1++)
In Vivo Model	PDX model
Experiment 4 Reporting the Activity Date of This ADC				[2]
Efficacy Data	Tumor Growth Inhibition value (TGI)	80.00%	High FOLR1 expression (FOLR1+++)
In Vivo Model	PDX model
Experiment 5 Reporting the Activity Date of This ADC				[2]
Efficacy Data	Tumor Growth Inhibition value (TGI)	100.00%	High FOLR1 expression (FOLR1+++)
In Vivo Model	PDX model
Experiment 6 Reporting the Activity Date of This ADC				[2]
Efficacy Data	Tumor Growth Inhibition value (TGI)	100.00%	High FOLR1 expression (FOLR1+++)
In Vivo Model	PDX model

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 26 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.24 nM	Low FOLR1 expression (FOLR1+)
In Vitro Model	Lung squamous cell carcinoma	NCI-H1703 cells		CVCL_1490
Experiment 2 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.74 nM	Low FOLR1 expression (FOLR1+)
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 3 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.84 nM	Low FOLR1 expression (FOLR1+)
In Vitro Model	Lung non-small cell carcinoma	NCI-H2110 cells		CVCL_1530
Experiment 4 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.40 nM	Low FOLR1 expression (FOLR1+)
In Vitro Model	Skin squamous cell carcinoma	A431 cells		CVCL_0037
Experiment 5 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.42 nM	Low FOLR1 expression (FOLR1+)
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 6 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.70 nM	Low FOLR1 expression (FOLR1+)
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 7 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.80 nM	Low FOLR1 expression (FOLR1+)
In Vitro Model	Amelanotic melanoma	MDA-MB-435 cells		CVCL_0417
Experiment 8 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.20 nM	Low FOLR1 expression (FOLR1+)
In Vitro Model	Human papillomavirus-related endocervical adenocarcinoma	KB cells		CVCL_0372
Experiment 9 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.29 nM	Low FOLR1 expression (FOLR1+)
In Vitro Model	Amelanotic melanoma	MDA-MB-435 cells		CVCL_0417
Experiment 10 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.42 nM	Low FOLR1 expression (FOLR1+)
In Vitro Model	Plasma cell myeloma	OPM-2 cells		CVCL_1625
Experiment 11 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Effective Concentration (EC50)	3.18 nM	Low FOLR1 expression (FOLR1+)
In Vitro Model	Colon cancer	HT29 cells		CVCL_A8EZ
Experiment 12 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Effective Concentration (EC50)	3.59 nM	Low FOLR1 expression (FOLR1+)
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 13 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Effective Concentration (EC50)	7.90 nM	Low FOLR1 expression (FOLR1+)
In Vitro Model	Lung adenocarcinoma	A-549 cells		CVCL_0023
Experiment 14 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Effective Concentration (EC50)	9.18 nM	Low FOLR1 expression (FOLR1+)
In Vitro Model	Colon carcinoma	HCT 116 cells		CVCL_0291
Experiment 15 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Effective Concentration (EC50)	9.20 nM	Low FOLR1 expression (FOLR1+)
In Vitro Model	Lung adenocarcinoma	NCI-H1651 cells		CVCL_1484
Experiment 16 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.07 ng/mL	Moderate FOLR1 expression (FOLR1++)
Method Description	STRO-002 in lgrov1 cell.
In Vitro Model	Ovarian endometrioid adenocarcinoma	IGROV-1 cells		CVCL_1304
Experiment 17 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.35 ng/mL	High FOLR1 expression (FOLR1+++)
Method Description	STRO-002 in KB cell.
In Vitro Model	Human papillomavirus-related endocervical adenocarcinoma	KB cells		CVCL_0372
Experiment 18 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.42 ng/mL	Low FOLR1 expression (FOLR1+)
In Vitro Model	Diffuse large B-cell lymphoma	SU-DHL-6 cells		CVCL_2206
Experiment 19 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.60 ng/mL	Low FOLR1 expression (FOLR1+)
In Vitro Model	Endometrial adenocarcinoma	Ishikawa cells		CVCL_2529
Experiment 20 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.10 ng/mL	Low FOLR1 expression (FOLR1+)
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 21 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.20 ng/mL	Moderate FOLR1 expression (FOLR1++)
In Vitro Model	Ovarian endometrioid adenocarcinoma	IGROV-1 cells		CVCL_1304
Experiment 22 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.80 ng/mL	Low FOLR1 expression (FOLR1+)
In Vitro Model	High grade ovarian serous adenocarcinoma	OVKATE cells		CVCL_3110
Experiment 23 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Effective Concentration (EC50)	3.60 ng/mL	Moderate FOLR1 expression (FOLR1++)
Method Description	SC209 in lgrov1 cell.
In Vitro Model	Ovarian endometrioid adenocarcinoma	IGROV-1 cells		CVCL_1304
Experiment 24 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Effective Concentration (EC50)	3.90 ng/mL	High FOLR1 expression (FOLR1+++)
Method Description	SC209 in KB cell.
In Vitro Model	Human papillomavirus-related endocervical adenocarcinoma	KB cells		CVCL_0372
Experiment 25 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Effective Concentration (EC50)	291.00 ng/mL	Moderate FOLR1 expression (FOLR1++)
Method Description	SC239 in lgrov1 cell.
In Vitro Model	Ovarian endometrioid adenocarcinoma	IGROV-1 cells		CVCL_1304
Experiment 26 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Effective Concentration (EC50)	400.00 ng/mL	High FOLR1 expression (FOLR1+++)
Method Description	SC239 in KB cell.
In Vitro Model	Human papillomavirus-related endocervical adenocarcinoma	KB cells		CVCL_0372

References

Ref 1	Discovery of STRO-002, a Novel Homogeneous ADC Targeting Folate Receptor Alpha, for the Treatment of Ovarian and Endometrial Cancers. Mol Cancer Ther. 2023 Feb 1;22(2):155-167.
Ref 2	Discovery of STRO-002, a Novel Homogeneous ADC Targeting Folate Receptor Alpha, for the Treatment of Ovarian and Endometrial Cancers. Mol Cancer Ther. 2023 Feb 1;22(2):155-167.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.

Payload Information

Citation

Visitor Map

Correspondence

Prof. Feng ZHU (zhufeng@zju.edu.cn)

Prof. Xiaowu DONG (dongxw@zju.edu.cn)

Prof. Luo FANG (fangluo@zjcc.org.cn)